Cerebral Venous Thrombosis
Authors:
- Salma I. PatelSPSalma I. Patel
- Hiba ObeidHOHiba Obeid
- Lana MattiLMLana Matti
- Harish RamakrishnaHRHarish Ramakrishna
- Fadi E. ShamounFSFadi E. Shamoun
- 1 November 2015
- journal article
- review article
- Published by Wolters Kluwer Health in The Neurologist
- Vol. 20 (5) , 80-88
Abstract
Cerebral venous thrombosis (CVT) is rare and involves thrombosis of the veins and sinuses of the brain, most commonly the superior sagittal sinus. Approximately 5 CVT cases occur per 1 million persons in western countries. CVT causes 0.5% of strokes. Early diagnosis is crucial to prevent such outcomes as hydrocephalus, intracranial hypertension, and further seizures. Standard medical treatment of CVT consists of low-molecular-weight heparin and endovascular thrombolysis. Small case reports have found that the newer oral anticoagulants can be used for CVT treatment; however, they are associated with increased risk of bleeding and other adverse effects. CVT can be triggered by an imbalance of the body's homeostasis or reduced action of the intrinsic antithrombotic mechanism. Factors influencing this change include infection, brain tumor, inflammatory conditions, genetic thrombophilias, head trauma that causes intracranial bleeding, and certain medications. CVT may cause brain infarction and increased intracranial pressure. Sometimes, idiopathic intracranial hypertension presents as the only clinical manifestation. Confirmation of the diagnosis typically is through neuroimaging. Current CVT treatment depends on disease extent and severity. CVT is a rare neurological disease with potentially serious implications and high neurological morbidity and mortality rates. Understanding the role of risk factors-such as genetic or acquired thrombophilia, pregnancy, use of oral contraceptives, and hyperhomocysteinemia-in CVT development is important. Although heparin and warfarin have been used for more than 50 years, newer oral anticoagulants (eg, dabigatran, rivaroxaban, apixaban) might offer an alternative to traditional therapy.Keywords
This publication has 68 references indexed in Scilit:
- Mutation in the Prothrombin Gene G20210A as a Cause of Cerebral Venous ThrombosisCase Reports in Medicine, 2012
- Cerebral Vein Thrombosis Misdiagnosed and MismanagedThrombosis, 2012
- Postpartum Cerebral Venous ThrombosisObstetrics & Gynecology, 2011
- Cerebral vein thrombosis: clinical manifestation and diagnosisBMC Neurology, 2011
- Acquired and Congenital Risk Factors associated with Cerebral Venous Sinus ThrombosisThrombosis Research, 2010
- Investigating suspected cerebral venous thrombosisBMJ, 2007
- Cerebral venous thrombosis: an updateThe Lancet Neurology, 2007
- Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control studyJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Cerebral venous sinus thrombosis presenting in the puerperiumEmergency Medicine Journal, 2006
- Headache as the only neurological sign of cerebral venous thrombosis: a series of 17 casesJournal of Neurology, Neurosurgery & Psychiatry, 2005